Robert Ferguson, PhD @upmc @IUMedSchool #ASCO22 #OncoTwitter @oncoalert TAMS Study For Cognitive Impairment

Robert Ferguson, PhD @upmc @IUMedSchool #ASCO22 #OncoTwit...

2 months
14 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Robert Ferguson, Ph.D., Biobehavioral Cancer Control Program at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO 2022 Abstract - Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: A model for remote clinical trial participation.

Synopsis:

The overarching goal of this experiment is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT), in treating chemotherapy-related cognitive impairment in breast cancer survivors (male or female). A multi-center, multi-clinician randomized control trial is being conducted (MAAT vs. supportive therapy attention control condition). This trial will also use functional magnetic resonance imaging (fMRI) in a working memory test to analyze pre-to-post treatment brain activity patterns in order to uncover underlying mechanisms of clinical therapeutic change in a subset of survivors.